FIRST RESULTS OF INTRAVENOUS APPLICATION OF BISPECIFIC ANTIBODY (CD3/CD19 SHR-1) TO PATIENTS WITH CD19 POSITIVE B-CELL MALIGNANCIES - A PHASE-1 STUDY

被引：0
|
作者：
VANHOUTEN, AA
HAAGEN, IA
CLARK, M
GEERARS, A
DELAU, W
BAST, EJEG
DEGAST, GC
机构：
[1] UNIV HOSP UTRECHT,DEPT HEMATOL,UTRECHT,NETHERLANDS
[2] UNIV HOSP UTRECHT,DEPT IMMUNOL,UTRECHT,NETHERLANDS
[3] UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE,CAMBS,ENGLAND
来源：
EXPERIMENTAL HEMATOLOGY | 1993年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1120 / 1120
页数：1
相关论文
共 50 条
  • [1] CYTOKINE RELEASE AFTER INTRAVENOUS ADMINISTRATION OF BISPECIFIC ANTIBODY (CD3/CD19, SHR-1) - A PHASE-I STUDY IN PATIENTS WITH CD19 POSITIVE B-CELL MALIGNANCIES
    VANHOUTEN, AA
    HAAGEN, IA
    CLARK, M
    GEERARS, A
    DELAU, W
    VROOM, TM
    BAST, EJEG
    DEGAST, GC
    BLOOD, 1993, 82 (10) : A580 - A580
  • [2] Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation
    Hatterer, Eric
    Barba, Leticia
    Noraz, Nelly
    Daubeuf, Bruno
    Aubry-Lachainaye, Jean-Pierre
    von der Weid, Benoit
    Richard, Francoise
    Kosco-Vilbois, Marie
    Ferlin, Walter
    Shang, Limin
    Buatois, Vanessa
    MABS, 2019, 11 (02) : 322 - 334
  • [3] T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16
    Lisa M. Pörtner
    Kathrin Schönberg
    Maryam Hejazi
    Daniela Brünnert
    Frank Neumann
    Lars Galonska
    Uwe Reusch
    Melvyn Little
    Rainer Haas
    Markus Uhrberg
    Cancer Immunology, Immunotherapy, 2012, 61 : 1869 - 1875
  • [4] Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5
    Lttgau, Sandra
    Deppe, Dorothee
    Meyer, Saskia
    Fertig, Regina
    Panjideh, Hossein
    Lipp, Martin
    Schmetzer, Oliver
    Pezzutto, Antonio
    Breitling, Frank
    Moldenhauer, Gerhard
    ANTIBODIES, 2013, 2 (02): : 338 - 352
  • [5] Tafasitamab Monoclonal antibody targeting CD19 Treatment of B-cell malignancies
    Narkhede, M.
    Cheson, B. D.
    DRUGS OF THE FUTURE, 2020, 45 (09) : 641 - 651
  • [6] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
    Sisi Wang
    Lijun Peng
    Wenqian Xu
    Yuebo Zhou
    Ziyan Zhu
    Yushan Kong
    Stewart Leung
    Jin Wang
    Xiaoqiang Yan
    Jian-Qing Mi
    Frontiers of Medicine, 2022, 16 : 139 - 149
  • [7] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
    Wang Sisi
    Peng Lijun
    Xu Wenqian
    Zhou Yuebo
    Zhu Ziyan
    Kong Yushan
    Leung Stewart
    Wang Jin
    Yan Xiaoqiang
    Mi JianQing
    Frontiers of Medicine, 2022, 16 (01) : 139 - 149
  • [8] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
    Wang, Sisi
    Peng, Lijun
    Xu, Wenqian
    Zhou, Yuebo
    Zhu, Ziyan
    Kong, Yushan
    Leung, Stewart
    Wang, Jin
    Yan, Xiaoqiang
    Mi, Jian-Qing
    FRONTIERS OF MEDICINE, 2022, 16 (01) : 139 - 149
  • [9] Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11
    Duell, Johannes
    Lukic, Dragana S.
    Karg, Margarete
    Reusch, Uwe
    Koch, Joachim
    Zhukovsky, Eugene A.
    Rajkovic, Erich
    Treder, Martin
    Rasche, Leo
    Eisele, Florian
    Einsele, Hermann
    Topp, Max S.
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (05) : 180 - 188
  • [10] T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 x CD3 or CD19 x CD16
    Poertner, Lisa M.
    Schoenberg, Kathrin
    Hejazi, Maryam
    Bruennert, Daniela
    Neumann, Frank
    Galonska, Lars
    Reusch, Uwe
    Little, Melvyn
    Haas, Rainer
    Uhrberg, Markus
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (10) : 1869 - 1875
12345